А rare case of lung nuclear protein in testis carcinoma
DOI:
https://doi.org/10.2478/AMB-2024-0025Keywords:
nuclear protein in testis, midline carcinoma, lung tumor, lung, NUT geneAbstract
Nuclear protein in testis carcinoma is a very rare but extremely aggressive high-grade carcinoma characterized by the presence of a fusion NUT gene – an oncogene. It is also called midline carcinoma because it mainly affects structures along the midline – head, neck, and lungs. We report a case of a woman with lung nuclear protein in testis carcinoma, diagnosed by bronchoscopic fibro-punch biopsy. The histological examination showed massive infiltration of bronchial wall of predominantly spindle-shaped neoplastic cells with unclear cytoplasmic borders. In some areas groups of rounded cells with clearly visible nucleoli and high mitotic rate were present. Foci with necrosis were also found. Immunohistochemistry showed positive expression of cytokeratin, p63, CD56 and nuclear protein in testis antibodies and negative reaction for TTF1 and chromogranin A in neoplastic cells. The proliferative activity of tumor cells was very high (> 70%). Immunohistochemical study of the nuclear protein in testis expression is mandatory in cases with poorly differentiated lung tumors, with predominantly midline mass.
References
French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol. 2012; 7:247-265. https://pubmed.ncbi.nlm.nih.gov/22017582/
French CA, Rahman S, Walsh EM, et al. NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism. Cancer Discov. 2014; 4:928-941. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125436/
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10:1243-60. Doi:10.1097/JTO.0000000000000630
French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol. 2004; 22:4135-4139. https://pubmed.ncbi.nlm.nih.gov/15483023/
Stelow EB, Bellizzi AM, Taneja K, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008; 32:828-834. https://pubmed.ncbi.nlm.nih.gov/18391746/
Stathis A, Zucca E, Bekradda M, et al. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discov 2016; 6:492-500. Doi:10.1158/2159-8290.CD-15-1335
Pezzuto F, Fortarezza F, Mammana M, et al. Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall. Histopathology. 2020. https://onlinelibrary.wiley.com/doi/10.1111/his.14166
Sholl LM, Nishino M, Pokharel S, et al. Primary pulmonary NUT midline carcinoma: clinical, radiographic, and pathologic characterizations. J Thorac Oncol. 2015; 10(6):951-9.
Stelow EB. A review of NUT midline carcinoma. Head Neck Pathol 2011; 5:31-5. Doi:10.1007/s12105-010-0235-x
Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067-1073. https://www.ncbi.nlm.nih.gov/pmc/articles/
Watanabe S, Hirano S, Mine S, et al. A case of endobronchial NUT midline carcinoma with intraluminal growth. Anticancer Res. 2015; 35:1607-12.
Rosenbaum DG, Teruya-Feldstein J, Price AP, et al. Radiologic features of NUT midline carcinoma in an adolescent. Pediatr Radiol. 2012; 42:249-252. https://pubmed.ncbi.nlm.nih.gov/22057302/
Lund-Iversen M, Groholt KK, Helland A, et al. NUT expression in primary lung tumours. Diagn Pathol. 2015;10:156
Miyoshi I, Aster JC, Kubonishi I, et al. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am J Pathol. 2001; 159(6):1987-92.
French CA. NUT midline carcinoma. Cancer Genet Cytogenet. 2010 Nov; 203(1):16-20. doi: 10.1016/j.cancergencyto.2010.06.007.
Liu S, Ferzli G NUT carcinoma: a rare and devastating neoplasm Case Reports 2018; 2018:bcr-2018-22652
Downloads
Published
Issue
Section
License
Copyright (c) 2024 S. Ivanova, R. Cherneva, M. Alexieva, G. Yankov (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.